Despite the fact that our in vitro results indicate that Orai1 is the primary actor in pulmonary vascular cells’ dysfunctions in PAH, we cannot exclude that in vivo CM5480 administration in MCT-PAH rats may inhibit Orai2 and/or Orai3, contributing to the benefit of CM5480. Here, ORAI3 is linked to pulmonary arterial hypertension.